Cite
APA Citation
Robinson, J., Farnier, M., Kastelein, J., Roth, E., Taskinen, M., Colhoun, H., Brunet, A., DiCioccio, A., Lecorps, G., Pordy, R., Baccara-Dinet, M., & Cannon, C. (2016). pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. Atherosclerosis, 252, e231–. http://access.bl.uk/ark:/81055/vdc_100039989445.0x000010